Ocean Biomedical announced that its Scientific Co-founder, Jack Elias, MD, co-authored new findings in the peer-reviewed journal Immunity that detail the mechanisms behind the role of chitinase 3-like-1 in the growth of triple negative breast cancer. The discoveries demonstrates that CHI3L1 stimulates neutrophil elaboration of NETs which block T cells from contacting and killing the breast cancer tumor. Additionally, the study provides further evidence of the potential impact of Ocean’s anti-Chi3L1 antibody in reversing this process and suppressing breast cancer tumor growth. This paper deepens the understanding of how CHI3L1 inhibits the body’s natural ability to fight breast cancer tumors. It reveals for the first time another complex pathway by which CHI3L1 inhibits the immune response to cancer, this time by inducing neutrophil recruitment and NETosis, which blocks T cell infiltration. The paper also provides yet another preclinical demonstration of the effectiveness of Ocean’s Anti-CHI3L1 antibody in reducing the tumor growth by targeting CHI3L1 and reversing the T cell blockade. This tumor control pathway, the paper asserts, is likely at work in a range of cancers beyond breast cancer, and “targeting CHI3L1 may promote anti-tumor immunity in various tumor types.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on OCEA:
- Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
- Ocean Biomedical receives Nasdaq notice over late filing
- Ocean Biomedical announces preclinical oncology data for VRON-0300
- Ocean Biomedical (NASDAQ: OCEA) Announces Positive Preclinical Oncology Data for VRON-0300, Presented at SITC 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion Therapeutics
- Ocean Biomedical (NASDAQ: OCEA) Announces First Patients Dosed by Joint Venture Partner Virion Therapeutics in Phase 1b Study of Novel Immunotherapy for Chronic Hepatitis B Virus Infection